Idexx Laboratories
IDXX
924 hedge funds and large institutions have $24B invested in Idexx Laboratories in 2022 Q3 according to their latest regulatory filings, with 60 funds opening new positions, 336 increasing their positions, 352 reducing their positions, and 85 closing their positions.
0.66% more ownership
Funds ownership: 87.87% → 88.53% (+0.66%)
5% less repeat investments, than reductions
Existing positions increased: 336 | Existing positions reduced: 352
3% less funds holding
Funds holding: 956 → 924 (-32)
7% less capital invested
Capital invested by funds: $25.9B → $24B (-$1.87B)
14% less funds holding in top 10
Funds holding in top 10: 21 → 18 (-3)
21% less call options, than puts
Call options by funds: $91.6M | Put options by funds: $116M
29% less first-time investments, than exits
New positions opened: 60 | Existing positions closed: 85
Top Buyers
| 1 |
Principal Financial Group
Des Moines,
Iowa
|
+$222M |
| 2 |
BlackRock
New York
|
+$132M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$97M |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
+$62.8M |
| 5 |
ESCM
Echo Street Capital Management
New York
|
+$61.4M |
Top Sellers
IDXX Hedge Fund Activity: Q3 2022 in Review
924 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Idexx Laboratories (IDXX) for Q3 2022, worth a combined $24B — down 7.2% from $25.9B a quarter earlier.
Sellers outnumbered buyers: 85 funds closed out of IDXX and 60 opened new positions — a net loss of 25 holders — while 352 trimmed existing stakes and 336 added.
The largest buyer was Principal Financial Group, adding an estimated $222M. The largest seller was T. Rowe Price Associates, cutting an estimated $241M.
- 924 institutional investors held Idexx Laboratories (IDXX) as of Q3 2022, down from 956 in Q2 2022.
- Funds reported $24B of Idexx Laboratories stock for Q3 2022, down 7.2% quarter-over-quarter.
- 60 funds opened new Idexx Laboratories positions in Q3 2022 and 85 closed out, a net change of -25 holders.
- The largest Idexx Laboratories buyer in Q3 2022 was Principal Financial Group, an estimated $222M added.
- The largest Idexx Laboratories seller in Q3 2022 was T. Rowe Price Associates, an estimated $241M sold.
Based on aggregated 13F filings for Q3 2022.